Sinonasal inhalation of dornase alfa in CF: A double-blind placebo-controlled cross-over pilot trial |
| |
Authors: | Mainz Jochen G Schiller Isabella Ritschel Christiane Mentzel Hans-Joachim Riethmüller Joachim Koitschev Assen Schneider Gerlind Beck James F Wiedemann Baerbel |
| |
Affiliation: | a Department of Paediatrics, Cystic Fibrosis Centre, University Hospital of Jena, Kochstrasse 2, 07740 Jena, Germany b Paediatric Radiology, University Hospital of Jena, Kochstrasse 2, 07740 Jena, Germany c Department of Paediatrics, University Hospital of Tubingen, Hoppe-Seyler-Str. 1, 72076 Tübingen, Germany d Department of Otorhinolaryngology, University Hospital of Tubingen, 72076 Tübingen, Germany e Department of Otorhinolaryngology, University Hospital of Jena, Lessingstraße 2, 07743 Jena, Germany f Department of Med. Informatics and Biometrics, Technical University Dresden, Fetscherstrasse 74, 01307 Dresden, Germany |
| |
Abstract: | ObjectiveThe paranasal sinuses are almost always involved in cystic fibrosis, and chronic rhinosinusitis and nasal polyps are very frequent in the disease. Hereby, the patients’ quality of life and their overall health are relevantly impaired. Although dornase alfa, a mucolytic agent, may also be effective in the upper airways, deposition of inhaled drugs into paranasal sinuses is substantially limited. The novel PARI SINUS™ nebuliser has been shown in deposition studies to deliver aerosol into paranasal sinuses but has not yet been clinically tested. This DBPC pilot-trial applying dornase alfa aims to evaluate outcome parameters and sample sizes for a subsequent efficacy trial.MethodsPrimary outcome parameters assessed were the Sino-Nasal Outcome Test (SNOT-20, a disease-specific quality of life assessment tool) and ventilated volume as measured by magnetic resonance imaging. Five CF patients were randomised to inhale either dornase alfa or 0.9% NaCl for 28 days and, after a wash-out period of 28 days, crossed over to the alternative treatment.ResultsWhereas normal saline was not associated with relevant changes in SNOT-20 scores, dornase alfa improved quality of life (p = 0.043). MRI results showed no definite trend.ConclusionThis first clinical study with the novel device gives promising results for the new therapeutic concept of sinonasal inhalation with vibrating aerosols in regard to further analysis involving larger collectives. |
| |
Keywords: | Cystic fibrosis Paranasal sinus Nose Sinusitis Dornase alfa PARI SINUS&trade Quality of life |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|